Dariohealth presents new study demonstrating significant clinical impact of personalized digital interventions based on real-time data

New york, aug. 12, 2021 /prnewswire/ -- dariohealth corp. (nasdaq: drio), a pioneer in the global digital therapeutics market, today announced a new study at the american association of diabetes care and education specialists (adces) annual conference demonstrating the impact of dario's intelligent personalization platform. dario's latest presentation examined the impact of personalized clinical interventions delivered in real-time through the company's digital therapeutics platform.
DRIO Ratings Summary
DRIO Quant Ranking